Study guide

10.3 Medication Safety, Incident Analysis, and Quality Improvement

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

10.3 Medication Safety, Incident Analysis, and Quality Improvement

Key Takeaways Explain This Topic AI

A Just Culture distinguishes human error (inadvertent slip requiring console and system redesign), at-risk behavior (behavioral choice with unrecognized risk requiring coaching), and reckless behavior (conscious disregard of known risk requiring disciplinary action).

Root Cause Analysis (RCA) is a structured, retrospective analysis of critical incidents, whereas Failure Mode and Effects Analysis (FMEA) is a prospective, proactive risk assessment tool.

High-alert medications (PINCH: Potassium/concentrated electrolytes, Insulin, Narcotics/Opioids, Chemotherapy, Heparin/Anticoagulants) require specialized system safeguards due to elevated harm potential.

Error-reduction strategies follow a hierarchy: forcing functions and automated hard stops are high-leverage interventions, while warning labels, policies, and educational reminders represent low-leverage interventions.

Independent double-checks require two healthcare practitioners to separately and independently verify high-risk orders, calculations, and products without priming or bias.

Last updated: August 2026

10.3 Medication Safety, Incident Analysis, and Quality Improvement

Exam Focus: The PEBC Pharmacist Evaluating Examination evaluates the candidate's understanding of systems-based medication safety, incident analysis, and error prevention. Candidates must master James Reason's Swiss Cheese Model, the Just Culture framework, Root Cause Analysis ( R C A RCA RC A ), Failure Mode and Effects Analysis ( F M E A FMEA FME A ), ISMP Canada standards for high-alert medications and Tall Man lettering, the hierarchy of error-reduction strategies, and continuous quality improvement ( C Q I CQI CQ I ) reporting.

Taxonomy of Medication Safety

Understanding the precise distinctions between adverse events, adverse drug reactions, and medication errors is foundational to healthcare risk management. +-------------------------------------------------------------------------+

  • | MEDICATION INCIDENT RELATIONSHIPS |
  • +-------------------------------------------------------------------------+
  • | 1. MEDICATION ERROR: |
  • | Any PREVENTABLE event that may cause or lead to inappropriate |
  • | medication use or patient harm while in the control of the |
  • | healthcare professional, patient, or consumer. |
  • | |
  • | 2. ADVERSE DRUG EVENT (ADE): |
  • | An injury or harm resulting from medical intervention related to a |
  • | drug. ADEs include harm from medication errors (preventable ADEs) |
  • | and harm from adverse drug reactions (non-preventable ADEs). |
  • | |
  • | 3. ADVERSE DRUG REACTION (ADR): |
  • | A noxious, unintended response to a drug occurring at normal doses |
  • | used for prophylaxis, diagnosis, or therapy (inherently non- |
  • | preventable under appropriate prescribing). |
  • | |
  • | 4. NEAR MISS / CLOSE CALL: |
  • | An event, situation, or error that took place but was intercepted |
  • | and corrected before reaching the patient (e.g., pharmacist catches |
  • | a 10-fold dosing error during prescription verification). |
  • +-------------------------------------------------------------------------+
  • Systems-Based Safety versus the Person Approach

Person Approach: Focuses on the individual at the "sharp end" (the practitioner administering or dispensing the drug). Blames errors on forgetfulness, inattention, carelessness, or moral failing. Relies on punitive measures ("blame and shame"), which drive error reporting underground and fail to resolve underlying vulnerabilities.

Systems Approach: Recognizes that humans are inherently fallible and errors will occur. Focuses on the "blunt end" (the organizational structures, processes, technologies, and working environments). Aims to build resilient defense mechanisms, forcing functions, and safeguards that prevent errors from reaching the patient.

James Reason's Swiss Cheese Model

In James Reason's accident causation model, an organization's defense systems are represented as multiple slices of Swiss cheese lined up alongside one another. The holes in each slice represent individual system weaknesses:

Latent Conditions: Systemic organizational defects (e.g., poor staffing ratios, underfunded software, poorly designed look-alike packaging, excessive noise/distractions, inadequate training).

Active Failures: Direct slips, lapses, or mistakes committed by frontline practitioners at the bedside or dispensing counter.

An adverse event occurs only when the holes in all defensive slices momentarily align, allowing a hazard trajectory to pass through unobstructed and cause patient harm. +-------------------------------------------------------------------------+

  • | THE SWISS CHEESE ACCIDENT MODEL |
  • +-------------------------------------------------------------------------+
  • | HAZARD ---> [Slice 1: CPOE Order Entry] (Hole: Confusing dropdown) |
  • | |
  • | v
  • | [Slice 2: Pharmacist Check] (Hole: Phone distraction) |
  • | |
  • | v
  • | [Slice 3: Automated Cabinet] (Hole: Override active) |
  • | |
  • | v
  • | [Slice 4: Bedside Barcoding] (Hole: Scanner uncharged) |
  • | |
  • | v
  • | PATIENT HARM (Catastrophic Overdose) |
  • +-------------------------------------------------------------------------+
  • The Just Culture Framework in Pharmacy

A Just Culture creates an atmosphere of trust where healthcare workers are encouraged and rewarded for reporting safety-related information, while maintaining a clear line between acceptable and unacceptable human behavior. +-------------------------------------------------------------------------+

  • | DAVID MARX JUST CULTURE DECISION ALGORITHM |
  • +-------------------------------------------------------------------------+
  • | 1. HUMAN ERROR (Inadvertent Slip, Lapse, or Honest Mistake): |
  • | - Practitioner inadvertently misreads a poorly printed label |
  • | - Management Action: CONSOLE the practitioner; evaluate and redesign|
  • | system defenses, lighting, and packaging. |
  • | |
  • | 2. AT-RISK BEHAVIOR (Behavioral Choice with Underestimated Risk): |
  • | - Practitioner creates a workaround (e.g., borrowing medications |
  • | from another patient's cassette, disabling nuisance alerts) |
  • | believing the shortcut is harmless or necessary for efficiency. |
  • | - Management Action: COACH the practitioner; remove organizational |
  • | incentives for shortcuts, and address workflow bottlenecks. |
  • | |
  • | 3. RECKLESS BEHAVIOR (Conscious Disregard of Substantial Risk): |
  • | - Practitioner intentionally bypasses mandatory independent double- |
  • | check protocols while impaired or knowing harm is likely. |
  • | - Management Action: DISCIPLINARY and remedial regulatory action. |
  • +-------------------------------------------------------------------------+
  • Incident Analysis: Retrospective and Prospective Frameworks
  • 1. Root Cause Analysis (RCA) / Incident Analysis (Retrospective)

Root Cause Analysis (RCA) is a structured, multidisciplinary retrospective investigation conducted following a critical incident or sentinel event to identify underlying systemic latent failures rather than individual blame.

Key Steps:

Form a multidisciplinary team (pharmacists, nurses, physicians, quality leads, risk managers).

Reconstruct the chronological event sequence through chart review, computer logs, and staff interviews.

Identify contributing factors across all domains using the Canadian Incident Analysis Framework .

Determine fundamental root causes (ask "Why?" iteratively).

Formulate an actionable Quality Improvement plan with measurable outcome markers.

The 5 Whys Technique: Iteratively questioning why an event happened to drill down past immediate symptoms to foundational systemic failures.

Ishikawa (Fishbone) Cause-and-Effect Diagram: Categorizes contributing factors into five primary domains (the 5Ms/PEEP): People/Personnel, Processes/Methods, Equipment/Machines, Environment, and Management/Organization .

2. Failure Mode and Effects Analysis (FMEA / HFMEA) (Prospective)

Failure Mode and Effects Analysis (FMEA) is a proactive, prospective risk assessment tool used to evaluate a new process or clinical technology before implementation to identify vulnerabilities and prevent errors.

Steps:

Map out every individual step of the proposed process (e.g., robotic dispensing implementation).

Brainstorm potential Failure Modes (what could go wrong at each step?).

Determine the potential Failure Effects and causes.

Assign numerical scores (scaled 1 to 10) for:

Severity ( S S S ): How severe is the clinical impact if the failure occurs?

Occurrence ( O O O ): How frequently is the failure likely to occur?

Detection ( D D D ): What is the likelihood that the failure will be detected before reaching the patient? (1 = almost certain detection; 10 = undetectable) .

Calculate the Risk Priority Number ( R P N RPN RPN ): R P N = Severity ( S ) × Occurrence ( O ) × Detection ( D ) RPN = \text{Severity ($S$)} \times \text{Occurrence ($O$)} \times \text{Detection ($D$)} RPN = Severity ( S ) × Occurrence ( O ) × Detection ( D ) (RPN values range from 1 to 1,000; steps with the highest RPNs are prioritized for redesign).

High-Alert Medications and ISMP Canada Standards

The Institute for Safe Medication Practices Canada (ISMP Canada) defines high-alert medications as drugs that bear a heightened risk of causing significant patient harm when used in error.

The PINCH High-Alert Mnemonic

P - Potassium and Concentrated Electrolytes: Concentrated Potassium Chloride ( K C l ≥ 2 mmol/mL KCl \ge 2\text{ mmol/mL} K Cl ≥ 2 mmol/mL ), Sodium Chloride injection ( > 0.9 % > 0.9\% > 0.9% ), Potassium Phosphate. Mandatory Safeguard: Ban concentrated electrolyte ampoules/vials from patient care floor stock; dispense only as premixed, diluted IV bags from the pharmacy.

I - Insulin: Subcutaneous and IV infusions. Rapid-acting vs long-acting analog mix-ups; U-500 concentration errors. Safeguard: Dedicated insulin syringes, independent double-checks, standardized protocols.

N - Narcotics and Opioids: Hydromorphone, morphine, fentanyl, methadone, oxycodone. Safeguard: Hydromorphone is ~5 times more potent than IV morphine; color-coded packaging; locked automated dispensing cabinets.

C - Chemotherapy / Cytotoxic Agents: Parenteral and oral antineoplastic agents (e.g., methotrexate daily vs weekly dosing errors; vincristine fatal intrathecal administration). Safeguard: Vincristine dispensed in minibags, NEVER in syringes; clear warning labels.

H - Heparin and Anticoagulants: Unfractionated heparin, low-molecular-weight heparins (enoxaparin, dalteparin), direct oral anticoagulants, warfarin. Safeguard: Separate storage of high-dose heparin flushes ( 10 , 000 units/mL 10,000\text{ units/mL} 10 , 000 units/mL ) from standard catheter flushes ( 10 to 100 units/mL 10\text{ to }100\text{ units/mL} 10 to 100 units/mL ).

Look-Alike Sound-Alike (LASA) Medications & Tall Man Lettering

ISMP Canada and Health Canada recommend Tall Man Lettering (capitalizing distinctive letter strings) to distinguish easily confused drug name pairs.

Generic Drug 1 Generic Drug 2 Clinical Danger of Confusion

hydrOXYzine hydrALAZINE Antihistamine vs potent vasodilator antihypertensive (hypotensive crisis).

predniSONE predniSOLONE Different dosage formulations and metabolic conversions.

vinCRIStine vinBLAStine Fatal neurotoxicity vs severe bone marrow suppression.

DOPamine DoBUTamine Vasopressor/inotropic agent mix-ups.

cloZAPine cloNIDine Antipsychotic (agranulocytosis risk) vs central alpha-2 agonist.

traMADol traZODone Opioid analgesic vs serotonergic sedative-antidepressant.

Prohibited Error-Prone Abbreviations

  • Prohibited Abbreviation Intended Meaning Misinterpretation Risk Mandatory Safe Terminology
  • U or u Unit Misread as '0' (zero), '4', or 'cc' (10 U read as 100). Write "unit" or "units"

QD or QOD Every day / Every other day Misread as QID (four times daily) or each other. Write "daily" or "every other day"

Trailing zero (e.g., 5.0 mg) 5 mg Misread as 50 mg if decimal point is missed. Write "5 mg" (NEVER use trailing zeros)

Lack of leading zero (e.g., .5 mg) 0.5 mg Misread as 5 mg if decimal is missed. Write "0.5 mg" (ALWAYS use leading zeros)

MSO4 or MgSO4 Morphine or Magnesium sulfate Confused for each other (fatal opioid overdose). Write "morphine" or "magnesium sulfate"

Hierarchy of Error-Reduction Strategies

ISMP Canada ranks error-reduction strategies based on their leverage and human reliance. +-------------------------------------------------------------------------+

  • | HIERARCHY OF ERROR REDUCTION STRATEGIES |
  • +-------------------------------------------------------------------------+
  • | HIGH-LEVERAGE (Most Effective - System-Focused): |
  • | - Forcing Functions & Physical Constraints |
  • | (e.g., ENFit enteral connectors incompatible with IV luer lines) |
  • | - Automation & Computerized Hard Stops |
  • | (e.g., Smart Infusion Pumps with Dose Error Reduction Systems [DERS])|
  • | |
  • | MEDIUM-LEVERAGE (Moderately Effective - Process-Focused): |
  • | - Standardization & Simplification (Preprinted order sets) |
  • | - Independent Double-Checks (Two practitioners verify independently) |
  • | - Visual Differentiation (Tall Man lettering, color-coded bins) |
  • | |
  • | LOW-LEVERAGE (Least Effective - Human-Focused): |
  • | - Auxiliary warning labels and pop-up soft alerts |
  • | - Policies, standard operating procedures, and written rules |
  • | - Educational in-services, memos, and appeals to staff vigilance |
  • +-------------------------------------------------------------------------+
  • Independent Double-Checks

An independent double-check occurs when two healthcare practitioners separately and independently verify the prescriber's order, clinical calculation, product selection, and pump programming.

Critical Rule: The second checker must never be primed by the first checker (e.g., the first checker must NOT say, "I drew up 5 mg of morphine, can you confirm this?"). Priming introduces confirmation bias and drastically reduces error detection rates.

Continuous Quality Improvement (CQI) in Canadian Pharmacies

Provincial pharmacy regulatory bodies mandate participation in standardized Continuous Quality Improvement (CQI) programs (e.g., AIMS in Ontario, SafetyNet in British Columbia, COMPASS in Saskatchewan).

Mandatory Anonymous Reporting: Pharmacies must record all medication incidents and near misses into an accredited national repository (e.g., CPhIR - Community Pharmacy Incident Reporting via ISMP Canada; NSIR - National System for Incident Reporting via CIHI).

Quarterly Safety Meetings: Pharmacy teams must conduct regular multidisciplinary reviews of incident trends and analyze root causes.

Plan-Do-Study-Act (PDSA) Cycles: Rapid cycles of testing quality improvements in small-scale practice environments before implementing system-wide changes.